Oaktree Acquisition Corp. III Life Sciences Unit (OACCU)

Verona Pharma reported strong financial results for Q4 and 2024, with its product Ohtuvayre (ensifentrine) recording net sales of $36.6 million in Q4 and $42.3 million in 2024. The company also announced an amended strategic financing with Oaktree and OMERS, including a term loan facility increase and access to additional funding.